Drug firm Zydus Cadila gets USFDA nod from US health regulator to market skin cream
- Country:
- India
Drug firm Zydus Cadila Monday said it has received a final nod from the US health regulator to market generic Desoximetasone cream used for the treatment of various skin conditions.
The approval from the United States Food and Drug Administration (USFDA) is to market Desoximetasone cream USP 0.25 per cent in America, Zydus Cadila said in a statement.
The product will be manufactured at the group's topical manufacturing facility at Ahmedabad, it added.
"Desoximetasone is a strong corticosteroid, used to treat a variety of skin conditions such as eczema, dermatitis, allergies and rash," it said.
It reduces the swelling, itching and redness that can occur in these types of conditions, it added.
The group now has 219 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs).
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 383.10 per scrip on the BSE, down 0.88 per cent from its previous close.
(With inputs from agencies.)
ALSO READ
GLOBAL MARKETS-Asian shares fall as US yields hold near 4-month high, earthquake hits
MORNING BID EUROPE-Markets brace for supply chain aftershock
China stocks track Asia markets lower on US rate cut concerns
Stock market today: Asian shares drop after Wall Street sinks on rate worries
GLOBAL MARKETS-Asian shares fall as US yields hold near 4-month high, earthquake hits
Google News